Companies
/
Neuralink
7
Healthtech
$53.4B
+$277.25
7,508.29%
30 days ago
$3.69
Create an account to view live offerings, pricing, and market activity.
Sign up with Augment to see the latest market activity.
Sign in to view offerings and live market activity.
Neuralink is a developer of brain-machine interfaces, building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world.
Neuralink was founded in 2016 by Elon Musk along with a team of neuroscientists and engineers, pursuing brain-computer interface technology that surgically implants a device, called the "Link," directly into a patient's brain to record neural activity and translate detected signals into computer commands, initially targeting patients with severe paralysis from conditions such as spinal cord injury or ALS who have lost the ability to move or speak, with the technology intended to let such patients control a computer cursor, type, or otherwise interact with digital devices using thought alone. Neuralink has continued to build clinical momentum through 2026, with media reports in April highlighting an early patient reaching 100 days of hands-free computer use with a Neuralink implant, while the company has said it is expanding its ambitions beyond computer cursor control and into enabling direct communication: its "VOICE" clinical study has demonstrated progress toward decoding intended speech directly from brain signals in ALS patients, an important step toward addressing a broader range of neurological conditions affecting communication. By the end of the second quarter of 2026, Neuralink had reportedly implanted its device in more than 20 patients across multiple clinical studies and countries, up from just a handful of patients in 2024, reflecting an accelerating pace of clinical trial expansion. In Augment's Q2 2026 Power 20 rankings, Neuralink rose four positions to #6, driven by the single largest quarterly price gain of any Power 20 company: its estimated secondary-market share price rose 127.8% during the quarter, more than doubling its implied market capitalization to approximately $56.6 billion, a repricing the rankings attributed primarily to accumulating clinical trial progress rather than any single new funding announcement, since Neuralink has raised a comparatively modest $1.3 billion in total funding relative to its now much larger implied valuation.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
